Sudbury-based RNA Diagnostics Inc. has received $100,000 towards the development of a RNA Disruption Assay (RDA), an innovative diagnostic product used in cancer management.
The diagnostic tool was discovered by Dr. Amadeo Parissenti, former cancer research chair for Sudbury Regional Hospital's Regional Cancer Program, during breast cancer clinical trials. When administered early on in treatment, RDA can help determine if chemotherapy treatment is working, or whether it should be modified or discontinued.
“We are very excited about the positive impact this funding will have on our ability to bring to market a new product that holds the prospect of revolutionizing how cancer treatments are administered here in Canada and throughout the world,” Parissenti said in a news release. “Today's announcement will enable RNA Diagnostics Inc. to commercialize a ground-breaking new product that may help to reduce health-care costs, while ensuring patients receive the most effective treatment available.”
Funding comes under FedNor's Northern Ontario Development Program, which supports projects that strengthen community economic development, enhance business growth and facilitate innvoation throughout the region.
.jpeg;w=120;h=80;mode=crop)
